Quantcast

Latest Lintuzumab Stories

2014-06-12 04:22:18

SEATTLE, June 12, 2014 /PRNewswire/ -- CTI BioPharma Corp. (CTI) (NASDAQ and MTA: CTIC) today announced the initiation of an international cooperative group Phase 2 clinical trial of tosedostat in combination with low-dose cytarabine in older patients with Acute Myeloid Leukemia (AML) or high risk Myelodysplastic Syndrome (MDS). Tosedostat is a first-in-class selective inhibitor of aminopeptidases, which are required by tumor cells to provide amino acids necessary for growth and tumor...

2014-06-10 08:31:13

Study Meets Pre-Specified CR/CRi Rate in First Nine Patients SAN DIEGO, June 10, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced preliminary response data from the first stage of a two-stage, open-label Phase II clinical study of its investigational drug candidate Pracinostat in combination with Vidaza(®) (azacitidine) in elderly patients with newly diagnosed acute myeloid...

2014-04-25 09:23:29

CPX-351 treatment leads to higher chances of remission compared to standard options in AML Moffitt Cancer Center researchers say clinical trials for a new experimental drug to treat acute myeloid leukemia (AML) are very promising. Patients treated with CPX-351, a combination of the chemotherapeutic drugs cytarabine and daunorubicin, are showing better responses than patients treated with the standard drug formulation. "Acute myeloid leukemia is an aggressive blood cancer with very low...

2014-02-28 08:25:51

SAN DIEGO, Feb. 28, 2014 /PRNewswire/ -- MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company's investigational drug Pracinostat for the treatment of acute myeloid leukemia (AML). (Logo: http://photos.prnewswire.com/prnh/20120628/LA32362LOGO) "We are very pleased to receive this orphan drug...

2013-12-18 13:10:26

Researchers at the Moffitt Cancer Center have discovered a control mechanism that can trigger the development of myelodysplastic syndromes (MDS), a group of blood cancers.  This finding may lead to therapies capable of preventing the progression of these diseases. MDS primarily affects older individuals, with approximately 12,000 new cases diagnosed each year. In MDS, a person’s blood is not able to make one or more types of healthy blood cells — red blood cells, white blood cells or...

2013-12-09 14:01:57

Findings from nationwide study led by Children's Mercy researcher highlighted at American Society of Hematology Meeting The addition of a monoclonal antibody called gemtuzumab combined with standard chemotherapy has been shown to significantly reduce the risk of relapse and increase rates of disease-free survival in pediatric patients with acute myeloid leukemia (AML). Post-treatment relapse rates are a major indicator of potential for long-term survival in children with the disease....


Word of the Day
Cthulhu
  • A gigantic fictional humanoid alien god being described with a head resembling an octopus and dragon wings and claws, around whom an insane cult developed.
  • Pertaining to the mythos of Cthulhu and additional otherworldly beings created by H. P. Lovecraft or inspired by his writings and imitators.
This word was invented in 1926 by H.P. Lovecraft for his short story, 'The Call of Cthulhu.' 'Cthulhu' may be based on the word 'chthonic,' which in Greek mythology refers to the underworld.
Related